ML20006B589

From kanterella
Jump to navigation Jump to search
Ack Receipt of Re M Brucer Comments Supporting Petition for Rulemaking to Revise 10CFR35 Regulations.Nrc Currently Reexamining Regulations Governing Use of Radiopharms in Nuclear Medicine
ML20006B589
Person / Time
Issue date: 01/26/1990
From: Rathbun D
NRC OFFICE OF GOVERNMENTAL & PUBLIC AFFAIRS (GPA)
To: Deconcini D
SENATE
Shared Package
ML20006B590 List:
References
RULE-PRM-35-9 CCS, NUDOCS 9002050108
Download: ML20006B589 (2)


Text

i.

. Caggk UNITED STATES J

.'].

3 NUCLEAR REGULATORY COMMISSION 5

[

WASHINGTON, D, C. 20006 January 26, 1990 The Honorable Dennis DeConcini United States Senate

. Washington, D. C.

20510-

Dear Senator DeConcini:

This is.to acknowledge receipt of your letter dated January 22, 1990, transmitting correspondence from your constituent, Dr. Marshall Brucer, in support of a petition for rulemaking to revise 10 CFR 35 Regulations.

The petition for rulemaking was submitted to the Nuclear Regulatory Comission (NRC) by the American College of Nuclear Physicians and>the Society of Nuclear Medicine. The petitioners requested that the NRC modify current regulations to allow: :(a) the use of radiopharmaceuticalsL for therapeutic indications not listed in the package insert-(diagnostic indications are not restricted by current' regulations), (b) deviations from the manufacturer's instructions in preparing radiopharmaceuticals..

and(c)compoundingradiopharmaceuticalsfromreagentchemicals.

TheNRCpublisitadaFederal-Registernotice.(54-FR38239, September 15,

~

1989)', announcing receipt of the petition _ and providing a 90-day. public coment period. We have received more than 400 conenent letters.

In light of the information submitted by the petitioners and the commenters, the NRC is currently reexamining its-regulations governing the.

l use of radiopharmaceuticals in nuclear medicine. The' issues raised will be addressed in a ruleliiaking proceeding specifically designed to resolve -

the petition.

During this rulemaking process, the NRC will consult with the Food and Drug Administration, which approves the package: inserts 'and the manufacturer's instructions, and the State Boards.ofLPharmacy and-invite their views regarding the resolution of this petition.

I want to assure you that the comments 'of your constituent will be considered along with the others in reexamining our regulations. However, it would be premature-to predict the outcome of the reexamination-before completion of the rulemaking proceeding..

I trust this information is responsive to your request.

Sincerely,

.s -

Dennis K. Rathbun, Director Congressional-Affairs Fl)M~ g U SONSCAN Office of Governmental and

'Public Affairs 900205cios 900126 fCk PRM pR PDC f e-1 (.

i p

.-e m.

i.

h.

l t-f.h.. MgG4A. :.

. w E

l l

l i

0 1

Letter also verbally approved by Jim Blaha and Mike-Weber 96..

(per Dennis Rathbun/Betsy Keeling) pyt.,

/-//

l l

1 l

c,----

w

---y

,.y.-

,,,.-r-y

_w,,._,,.,y.

,,,,,.,,,.........,.m.,,,,,,,,,,g.

,, -.-%,.#,,-,,,,,w-,,w,,,%, _

-,..n...py,,,..,,,